Patent medicine the patent medicines, some of their makers began replacing the opium tincture laudanum with acetanilide, a particularly toxic non-steroidal anti-inflammatory drug with analgesic as well as antipyretic properties that had been introduced into medical practice under the name "Antifebrin" by A. Cahn and P. Hepp in 1886. But this ingredient change probably killed more of the nostrum's users than the original narcotics did, since acetanilide not only caused an alarming cyanosis due to methemoglobinemia but was later discovered to cause liver and kidney damage. The occasional reports of acetanilide-induced cyanosis prompted the search for supposedly less toxic aniline derivatives, such
Botanical drug the substance being developed as a botanical drug has been used in traditional medicine, it may be possible to begin initial, small clinical trials without conducting extensive toxicology testing. However, toxicity testing is required before beginning larger clinical trials and trials that will be used to get approval to sell a botanical drug. The endogenous Chinese pharmaceutical industry is made up mostly of companies that make herbal traditional chinese medicines and sell them over the counter; the US regulatory pathway is similar to that established by the China Food and Drug Administration. The European regulatory pathway is also similar. As